Gilead terminates trial of long-acting HIV pills Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 2 April, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

SPOTLIGHT In Focus How pharma is capitalizing on the sudden revival and success of an old asthma drug

news Immunovant's FcRn drug fails in a pair of Phase 3 trials in thyroid eye disease Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss Gilead ends a Phase 2/3 trial of long-acting HIV pills, following earlier clinical hold Peer Review Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

John Carroll’s R&D 15 report is back — and this year, he’s bringing some of the industry’s top research chiefs into the conversation to break down what the data means, what’s shifting, and where biopharma R&D is headed. Join us to find out what comes next.

ENDPOINTS PHARMA To counter China, FDA chief wants to speed process for approving new drug trials Making custom CRISPR therapies could be harder than initially thought Novo cuts 400 jobs in Indiana as Scholar Rock refiles drug linked to the factory FDA delays decision on Orca Bio cell therapy after filing more manufacturing data

Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera

in case you missed it 1. Updated: Lilly wins FDA approval of anti-obesity pill orforglipron, setting up new battle with Novo 2. Paragon offshoot Korsana to go public in reverse merger for Alzheimer's work 3. News Briefing Amgen, Zai Lab team up on DLL3; Janux gets $35M milestone payment 4. IO Biotech will file for bankruptcy after failure of cancer vaccine in key trial 5.